Fundraising Fox
Anavex Life Sciences
NASDAQ: AVXLPortola Valley, US · 46 employees on LinkedIn · 1 known investors
Find your way into Anavex Life Sciences
220 people in our graph share verified history with the Anavex Life Sciences team — schools, employers, funds. One of them is your warm intro.
Jiong Maunlockedknows Christopher U. Missling · together at Anavex Life Sciences (overlapped)
×2knows the team · via Curis Inc
×8knows the team · via Deutsche Bank
knows the team · via Brimberg & Co.
Anavex Life Sciences is a clinical-stage biopharmaceutical company developing oral therapeutics for central nervous system disorders, including Alzheimer's disease, Rett syndrome, and Fragile X syndrome. Its lead compound is ANAVEX 2-73 (blarcamesine), targeting early Alzheimer's and neurodevelopmental rare diseases.
Founders & leadership
AV
Alexandre VamvakidesCo-founder
AP
Axel PaegerBoard Member (founder)
HL
Harvey LalachExecutiveHarvey Lalach has over 25 years of experience in project management and business development across public and private companies, with 17 years focused on biotech. He co-founded Anavex Life Sciences in 2006 and served as President and Director for seven years, and later co-founded TheraPten Biosciences in 2016.
GT
George TidmarshExecutive
CU
Christopher U. MisslingExecutiveChristopher U. Missling is President and CEO of Anavex Life Sciences, a biopharmaceutical company developing therapies for central nervous system disorders. He holds a PhD in Metallorganic Chemistry and an MBA from Northwestern University's Kellogg School of Management, and has over two decades of experience in biotechnology and financial strategy from prior roles at ImmunoGen, Aventis (now Sanofi), and Deutsche Bank.
Board
SL
Sean LowryBoard director
JC
John ChisholmBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$10M disclosed across 2 rounds · 2012–2014
▶$10MraisedApr 2014 · 11 investors · BiotechnologyRule 506(b)
▶$10MraisedApr 2014 · 11 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Christopher U. MisslingExecutive Officer, Director
- Athanosios SkarpelosDirector
- Offering amount
- $10M
- Amount sold
- $10M
- Minimum investment
- $106.8K
- Sales commissions
- $700K
- Placement agents
- Maxim Group LLC
- First sale
- Mar 2014
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$10KraisedFeb 2012 · 1 investors · BiotechnologyRule 506(b)
▶$10KraisedFeb 2012 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Sean LowryDirector
- Alexandre VamvakidesExecutive Officer
- John ChisholmDirector
- Harvey LalachExecutive Officer, Director
- George TidmarshExecutive Officer, Director
- Offering amount
- $10K
- Amount sold
- $10K
- First sale
- Feb 2012
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Anavex Life Sciences do?
- Anavex Life Sciences is a clinical-stage biopharmaceutical company developing oral therapeutics for central nervous system disorders, including Alzheimer's disease, Rett syndrome, and Fragile X syndrome. Its lead compound is ANAVEX 2-73 (blarcamesine), targeting early Alzheimer's and neurodevelopmental rare diseases.
- Who founded Anavex Life Sciences?
- Anavex Life Sciences was founded by Alexandre Vamvakides, Axel Paeger.
- Who are Anavex Life Sciences's investors?
- Anavex Life Sciences's investors include Sofinnova Ventures.
- How much funding has Anavex Life Sciences raised?
- Anavex Life Sciences has disclosed $10M raised across 2 rounds.
- Where is Anavex Life Sciences headquartered?
- Anavex Life Sciences is headquartered in Portola Valley, US.